PharmacyCodes



Oxibutinina [Inn-Spanish] en es it fr

Oxibutinina [Inn-Spanish] Brand names, Oxibutinina [Inn-Spanish] Analogs

Oxibutinina [Inn-Spanish] Brand Names Mixture

  • No information avaliable

Oxibutinina [Inn-Spanish] Chemical_Formula

C22H31NO3

Oxibutinina [Inn-Spanish] RX_link

http://www.rxlist.com/cgi/generic/ditropan.htm

Oxibutinina [Inn-Spanish] fda sheet

Oxibutinina_[Inn-Spanish] FDA

Oxibutinina [Inn-Spanish] msds (material safety sheet)

Oxibutinina_[Inn-Spanish] MSDS

Oxibutinina [Inn-Spanish] Synthesis Reference

Brit. pat. 940540 (1963 to Mead Johnson)

Oxibutinina [Inn-Spanish] Molecular Weight

357.486 g/mol

Oxibutinina [Inn-Spanish] Melting Point

129-130 oC

Oxibutinina [Inn-Spanish] H2O Solubility

No information avaliable

Oxibutinina [Inn-Spanish] State

Solid

Oxibutinina [Inn-Spanish] LogP

4.683

Oxibutinina [Inn-Spanish] Dosage Forms

Patch; Syrup; Tablet; Tablet (extended-release)

Oxibutinina [Inn-Spanish] Indication

For the treatment of overactive bladder.

Oxibutinina [Inn-Spanish] Pharmacology

Oxybutynin is an antispasmodic, anticholinergic agent indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. Oxybutynin relaxes bladder smooth muscle. Oxybutynin exhibits only one-fifth of the anticholinergic activity of atropine on the rabbit detrusor muscle, but four to ten times the antispasmodic activity. Antimuscarinic activity resides predominantly in the R-isomer.

Oxibutinina [Inn-Spanish] Absorption

Rapidly absorbed from gastrointestinal tract.

Oxibutinina [Inn-Spanish] side effects and Toxicity

LD50=1220 mg/kg (Orally in rats, Goldenthal)

Oxibutinina [Inn-Spanish] Patient Information

PATIENT INFORMATION
Patient should be informed that oxybutynin may produce drowsiness or blurred vision. Alcohal may enhance the drowsiness caused by anticholinergic agents. Fever and heat stroke can occur while anticholinergics are administered in the presence of high environmental temparature. Medication should be taken with the aid of liquids at approximately the same time each day. Patients should not chew, divide, or crush tablets.

Oxibutinina [Inn-Spanish] Organisms Affected

Humans and other mammals